Peter Palese

Affiliations: 
Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Area:
Microbiology Biology
Google:
"Peter Palese"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Folschweiller N, Vanden Abeele C, Chu L, et al. (2022) Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. The Lancet. Infectious Diseases
González-Domínguez I, Martínez JL, Slamanig S, et al. (2022) Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice. Biorxiv : the Preprint Server For Biology
Pitisuttithum P, Luvira V, Lawpoolsri S, et al. (2022) Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. Eclinicalmedicine. 45: 101323
Ponce-de-León S, Torres M, Soto-Ramírez LE, et al. (2022) Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. Medrxiv : the Preprint Server For Health Sciences
Houser KV, Chen GL, Carter C, et al. (2022) Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine
Bliss CM, Freyn AW, Caniels TG, et al. (2022) A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy : the Journal of the American Society of Gene Therapy
Guthmiller JJ, Han J, Utset HA, et al. (2021) Broadly neutralizing antibodies target a hemagglutinin anchor epitope. Nature
Tcheou J, Raskin A, Singh G, et al. (2021) Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Frontiers in Immunology. 12: 791764
Rathnasinghe R, Salvatore M, Zheng H, et al. (2021) Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Scientific Reports. 11: 22164
Sun W, Liu Y, Amanat F, et al. (2021) A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications. 12: 6197
See more...